Novartis Outsources OTC Production, Cuts SKUs To Speed Product Return
This article was originally published in The Tan Sheet
Executive Summary
Novartis AG is on target to reopen its OTC manufacturing facility in Lincoln, Neb., in May and begin shipments midyear, but concedes that only a “limited portfolio” will ship from the plant in 2012. It will outsource manufacturing to make up some of the difference and also aggressively will cut SKUs.